Home › Mild Cognitive Impairment › NCT05881239
Digital Accessible Remote Olfactory Mediated Health Assessments for Preclinical AD
Who can join
Ages 18 to 100 · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * A clinical or research consensus diagnosis of the patient's condition or control status. * Individuals that are at least 18 years of age at the time of enrollment. * Individuals that are no older than 100 years of age at the time of enrollment. Exclusion Criteria: * Primary pulmonary disease such as severe emphysema or asthma not under good medical control. * Current sinusitis, common cold, upper respiratory infection, or nasal polyps. * Current or recent (past 6 months) alcohol or substance dependence. A prior history of alcohol or substance abuse will not be grounds for exclusion. * Pregnancy. * Severe cognitive dysfunction that would preclude completion of the olfactory testing. * An adverse reaction to fragrances (ie. they trigger a severe asthmatic attack or nausea).
About the study
The goal of this study is to objectively test one's sense of smell, called olfaction, in participants with Subjective Cognitive Concerns (SCC), Mild Cognitive Impairment, Mild Behavioral Impairment (MBI), and age-matched controls. The main question it aims to answer is whether the AROMHA Brain Health Test could serve as a predictive biomarker of neurodegenerative disorders. This understanding will aid in the development of a noninvasive, cost-effective diagnostic tool that reliably and specifically distinguishes disease and normal aging populations.
Participants will take the approximately 45-minute AROMHA Brain Health Smell Test where they will peel and sniff labels on the physical smell cards and answer questions on the web-based app relating to what they smelled. Participants will undergo tests for odor intensity, odor identification, odor discrimination, and episodic olfactory memory, but will not be provided the results of these tests.
What is being tested
- AROMHA Brain Health Test (device)
Sponsor: Massachusetts General Hospital · Participants: 250 · Started: May 9, 2023
Contact the study team
- Mark W Albers, MD PhD · Phone: 617-724-7401
Official record on ClinicalTrials.gov — NCT05881239
Locations in the U.S.
| Massachusetts | Massachusetts General Hospital, Boston |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.